Edgewise Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

EWTX$48.74+8.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

STATEMENTS OF CASH FLOWS

(In thousands)


· · Year ended December 31,
· · 2025 · · 2024 · · 2023
Cash flows from operating activities · · · · · · · ·
Net loss	$(167,795)	$(133,813)	$(100,163)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	2,084	2,069	1,551
Stock-based compensation	34,752	24,712	17,560
Accretion of discount on marketable securities, net	(7,665)	(12,545)	(9,517)
Amortization of right-of-use asset	182	221	181
Changes in assets and liabilities:
Prepaid expenses and other assets	(7,963)	3,292	(3,553)
Accounts payable	272	1,737	(92)
Accrued compensation	2,374	4,361	1,663
Accrued other expenses and other liabilities	691	1,158	526
Lease liability	(748)	(220)	(104)
Net cash used in operating activities	(143,816)	(109,028)	(91,948)

Cash flows from investing activities
Purchases of marketable securities	(527,226)	(477,055)	(255,866)
Sales of marketable securities	67,384	15,794	20,118
Maturities of marketable securities	427,308	277,917	344,379
Purchases of property and equipment	(256)	(1,312)	(5,745)
Net cash (used in) provided by investing activities	(32,790)	(184,656)	102,886

Cash flows from financing activities
Proceeds from issuance of common stock, net of offering costs	187,362	239,147	52,618
Exercise of stock options	7,803	9,480	117
Payment of deferred offering costs	—	(262)	(165)
Proceeds from Employee Stock Purchase Plan	923	888	596
Net cash provided by financing activities	196,088	249,253	53,166

Net change in cash and cash equivalents	19,482	(44,431)	64,104
Cash and cash equivalents at beginning of period	41,666	86,097	21,993
Cash and cash equivalents at end of period	$61,148	$41,666	$86,097
Supplemental disclosures of non-cash investing and financing activities:
Right-of-use asset obtained in exchange for new operating lease liability, net of tenant improvement receivable	$—	$—	$1,110
Property and equipment purchases included in accounts payable and accrued other expenses	$199	$44	$227

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.